Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR for malignant ascites in cancer patients
NCT00182754Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2005
- Primary completion
- Sep 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of Octreotide long-acting injection in malignant ascites, sponsored by Cancer and Leukemia Group B. Started Oct 2005; status: completed.
02
Drugs
Octreotide long-acting injection
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT00182754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00182754.